256 related articles for article (PubMed ID: 18686042)
1. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.
Fowler S; Zhang H
AAPS J; 2008 Jun; 10(2):410-24. PubMed ID: 18686042
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.
Riley RJ; Wilson CE
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):557-72. PubMed ID: 25659570
[TBL] [Abstract][Full Text] [Related]
3. Inhibition and induction of cytochrome P450 and the clinical implications.
Lin JH; Lu AY
Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
[TBL] [Abstract][Full Text] [Related]
4. Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies.
Ericsson T; Sundell J; Torkelsson A; Hoffmann KJ; Ashton M
Xenobiotica; 2014 Jul; 44(7):615-26. PubMed ID: 24400699
[TBL] [Abstract][Full Text] [Related]
5. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
[TBL] [Abstract][Full Text] [Related]
6. Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards.
Kozakai K; Yamada Y; Oshikata M; Kawase T; Suzuki E; Haramaki Y; Taniguchi H
Drug Metab Pharmacokinet; 2012; 27(5):520-9. PubMed ID: 22498647
[TBL] [Abstract][Full Text] [Related]
7. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
[TBL] [Abstract][Full Text] [Related]
8. Strategies to in vitro assessment of major human CYP enzyme activities by using liquid chromatography tandem mass spectrometry.
Lahoz A; Donato MT; Castell JV; Gómez-Lechón MJ
Curr Drug Metab; 2008 Jan; 9(1):12-9. PubMed ID: 18220567
[TBL] [Abstract][Full Text] [Related]
9. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.
VandenBrink BM; Isoherranen N
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):66-77. PubMed ID: 20047147
[TBL] [Abstract][Full Text] [Related]
10. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS.
Di L; Kerns EH; Li SQ; Carter GT
Int J Pharm; 2007 Apr; 335(1-2):1-11. PubMed ID: 17137735
[TBL] [Abstract][Full Text] [Related]
12. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation.
Venkatakrishnan K; Obach RS
Curr Drug Metab; 2007 Jun; 8(5):449-62. PubMed ID: 17584016
[TBL] [Abstract][Full Text] [Related]
13. Cocktail-substrate approach-based high-throughput assay for evaluation of direct and time-dependent inhibition of multiple cytochrome P450 isoforms.
Kozakai K; Yamada Y; Oshikata M; Kawase T; Suzuki E; Haramaki Y; Taniguchi H
Drug Metab Pharmacokinet; 2014; 29(2):198-207. PubMed ID: 24172718
[TBL] [Abstract][Full Text] [Related]
14. An in vitro, high throughput, seven CYP cocktail inhibition assay for the evaluation of new chemical entities using LC-MS/MS.
Otten JN; Hingorani GP; Hartley DP; Kragerud SD; Franklin RB
Drug Metab Lett; 2011 Jan; 5(1):17-24. PubMed ID: 21198441
[TBL] [Abstract][Full Text] [Related]
15. Risk assessment of mechanism-based inactivation in drug-drug interactions.
Fujioka Y; Kunze KL; Isoherranen N
Drug Metab Dispos; 2012 Sep; 40(9):1653-7. PubMed ID: 22685217
[TBL] [Abstract][Full Text] [Related]
16. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
[TBL] [Abstract][Full Text] [Related]
17. System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes.
Parkinson A; Kazmi F; Buckley DB; Yerino P; Ogilvie BW; Paris BL
Drug Metab Pharmacokinet; 2010; 25(1):16-27. PubMed ID: 20208386
[TBL] [Abstract][Full Text] [Related]
18. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
19. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
Iga K
J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
Kalgutkar AS; Obach RS; Maurer TS
Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
